Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotherapy for urological malignancies.

Kent G Krejci1, Mary A Markiewicz, Eugene D Kwon

  • 1Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA.

The Journal of Urology
|January 10, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longitudinal Tumor Mutation Burden Dynamics in Advanced Prostate Cancer Using Circulating Tumor DNA Profiling.

Clinical genitourinary cancer·2026
Same author

Salvage lymph node dissection in oligo-recurrent prostate cancer patients: Mapping patterns of recurrence and factors associated with disease progression.

Urologic oncology·2026
Same author

Outcomes of stereotactic body radiotherapy for supraclavicular lymph node metastasis among patients with metastatic prostate cancer.

Clinical and translational radiation oncology·2026
Same author

LuRa: Efficacy and Safety of Radium-223 Following [<sup>177</sup>Lu]Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer.

Clinical genitourinary cancer·2026
Same author

PSA Zero Radiographic Disease Progression on PSMA PET/CT.

Cancers·2026
Same author

Scrotal uptake on PSMA PET in prostate cancer: differentiating metastases from benign and physiologic findings using ultrasound correlation.

Abdominal radiology (New York)·2026

Immunotherapy offers promising new treatments for urological cancers. Novel strategies like antibodies and vaccines aim to harness the immune system for tumor eradication, expanding therapeutic options.

Area of Science:

  • Urology
  • Immunology
  • Oncology

Background:

  • Immunotherapy, including Interleukin-2 for renal cell carcinoma and bacillus Calmette-Guerin for bladder cancer, is established in urological oncology.
  • Recent breakthroughs in immune system activation have led to novel immunotherapeutic strategies with in vivo promise.

Purpose of the Study:

  • To review current immunotherapy strategies for urological cancers.
  • To highlight promising novel approaches beyond established treatments.

Main Methods:

  • A MEDLINE literature search was conducted for immunotherapy in bladder, prostate, and renal cell carcinoma.
  • Promising animal and human studies were selected for inclusion.

Main Results:

  • Novel approaches include antitumoral antibodies, T-lymphocyte costimulatory molecule manipulation, new cytokines, and cancer vaccines.

Related Experiment Videos

  • Combining existing therapies is also explored to enhance efficacy.
  • These strategies aim to utilize the immune system to identify, target, and eradicate malignancies.

    • Conclusions:

    • The full potential of immunotherapy for urological malignancies remains largely unrecognized.
    • Expanding knowledge of the immune system may enhance tumor regression through manipulation.
    • This review presents the latest promising developments in the field.